Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 723.07

+2.7%

3:36 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	3/15/2018 1:31:52 PM
	Read Replies (1) of 3559

Cervical cancer, HPV associated: REGN2810 for platinum-refractory cervical cancer, P3-2L, (OS primary): clinicaltrials.gov Note: relative large trial, 3 y time frame for completion, and in collaboration with ISA Pharm. for chombo, seekingalpha.com MRK Pemb for cervical carcinoma NDA based on two trials: cohort of K-028 (P1b, ascopubs.org ), and cohort of K-158 ( clinicaltrials.gov ), ascopubs.org, ....NDA based on ORR! BMY Opdivo in combination with IDO1: seekingalpha.com Overall, for cervical cancer, development luck significant efforts from PD1/L1 players, suggest opportunity for REGN2810.... however, path to approval may be too long and costly.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next